Latest News and Press Releases
Want to stay updated on the latest news?
-
- Bavituximab Alone and in Combination with Docetaxel Elicit a Tumor-Specific Immune Response in PD-L1 Negative Tumors Extracted from NSCLC Patients - - Immune Modulating Results Consistent with...
-
TUSTIN, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that two preclinical abstracts and one clinical translation abstract are...
-
- Combination of Bavituximab and Paclitaxel Achieved an 85% Objective Response- - Design of Phase II Clinical Trial Underway - TUSTIN, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Peregrine...
-
- SUNRISE Phase III Lung Cancer Trial On Track to Complete Enrollment by Calendar Year-End - - Encouraging and Consistent Data from Immuno-Oncology Development Program Continue to Support...
-
TUSTIN, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
-
TUSTIN, Calif., March 5, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology...
-
TUSTIN, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology...